American Diabetes Association:  American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity: Consensus development conference of antipsychotic drugs and obesity and diabetes.  Diabetes Care   2004; 27:598–600http://www.ncbi.nlm.nih.gov/pubmed/14747245

 American Psychiatric Association:  Practice Guideline for the Treatment of Patients With Major Depressive Disorder , 3rd Edition.  Arlington, VA,  American Psychiatric Association,  2010. Available at: http://psychiatryonline.org/data/Books/prac/PG_Depression3rdEd.pdf

Athanasiou  MC;  Dettling  M;  Cascorbi  I;  Mosyagin  I;  Salisbury  BA;  Pierz  KA;  Zou  W;  Whalen  H;  Malhotra  AK;  Lencz  T;  Gerson  SL;  Kane  JM;  Reed  CR:  Candidate gene analysis identifies a polymorphism in HLA-DQB1 associated with clozapineinduced agranulocytosis.  J Clin Psychiatry   2011; 72:458–463

Ballon  JS;  Lieberman  JA:  Advances in the management of treatment-resistant schizophrenia.  Focus   2010; 8:475–487

Biederman  J;  Monuteaux  MC;  Spencer  T;  Wilens  TE;  MacPherson  HA;  Faraone  SV:  Stimulant therapy and risk for subsequent substance use disorders in male adults with ADHD: a naturalistic controlled 10-year follow-up study.  Am J Psychiatry   2008; 165:597–603. Focus 2008; 6:358–365

Birmaher  B;  Brent  D;  Bernet  W;  Bukstein  O;  Walter  H;  Benson  RS;  Chrisman  A;  Farchione  T;  Greenhill  L;  Hamilton  J;  Keable  H;  Kinlan  J;  Schoettle  U;  Stock  S;  Ptakowski  KK;  Medicus  J:  AACAP Work Group on Quality Issues: Practice parameter for the assessment and treatment of children and adolescents with depressive disorders.  J Am Acad Child Adolesc Psychiatry   2007; 46:1503–1526. Focus 2008; 6:379–400

Buchanan  RW;  Kreyenbuhl  J;  Kelly  DL;  Noel  JM;  Boggs  DL;  Fischer  BA;  Himelhoch  S;  Fang  B;  Peterson  E;  Aquino  PR;  Keller  W:  Schizophrenia Patient Outcomes Research Team (PORT): The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements.  Schizophr Bull   2010; 36:71–93

Buckley  PF;  Foster  A;  Miller  B:  Schizophrenia host vulnerability and risk of metabolic disturbances during treatment with antipsychotics.  Focus   2008; 6:172–179

Burt  VK;  Hedrick  VC (ed):  Clinical Manual of Women’s Mental Health .  Washington, DC,  American Psychiatric Publishing,  2005, pp 150

Byerly  M;  Suppes  T;  Tran  QV;  Baker  RA:  Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: recent developments and current perspectives.  J Clin Psychopharmacol   2007; 27:639–661

Casadio  P;  Fernandes  C;  Murray  RM;  Di Forti  M:  Cannabis use in young people: the risk for schizophrenia.  Neurosci Biobehav Rev   2011; 35:1779–1787

Citrome  L:  Role of sublingual asenapine in treatment of schizophrenia.  Neuropsychiatr Dis Treat   2011; 7:325–339

Citrome  L:  Vilazodone for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant -what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract   2012; 66:356–368

Citrome  L;  Weiss-Citrome  A:  A systematic review of duloxetine for osteoarthritic pain: what is the number needed to treat, number needed to harm, and likelihood to be helped or harmed? Postgrad Med   2012; 124:83–93

Cohen  LS;  Friedman  JM;  Jefferson  JW;  Johnson  EM;  Weiner  ML:  A reevaluation of risk of in utero exposure to lithium.  JAMA   1994; 271:146–150

Correll  CU;  Manu  P;  Olshanskiy  V;  Napolitano  B;  Kane  JM;  Malhotra  AK:  Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents.  JAMA   2009; 302:1765–1773

Coryell  W:  The search for improved antidepressant strategies: is bigger better? Am J Psychiatry   2011; 168:664–666

Cuijpers  P;  van Straten  A;  Andersson  G;  van Oppen  P:  Psychotherapy for depression in adults: a meta-analysis of comparative outcome studies. J Consult Clin Psychol 2008; 76:909–922.  Focus   2010; 8:75–91

Cunningham  J;  Yonkers  KA;  O’Brien  S;  Eriksson  E:  Update on research and treatment of premenstrual dysphoric disorder.  Harv Rev Psychiatry   2009; 17:120–137

 Diagnostic and Statistical Manual of Mental Disorders:  DSM-IV-TR , Fourth Edition, Text Revision.  Washington, DC,  American Psychiatric Association,  2000, pp 422

Dias  RS;  Lafer  B;  Russo  C;  Del Debbio  A;  Nierenberg  AA;  Sachs  GS;  Joffe  H:  Longitudinal follow-up of bipolar disorder in women with premenstrual exacerbation: findings from STEP-BD.  Am J Psychiatry   2011; 168:386–394

Dickerson  FB;  Lehman  AF:  Evidence-based psychotherapy for schizophrenia: 2011 update.  J Nerv Ment Dis   2011; 199:520

526. Reprinted in FOCUS 2012; 10:217-225.

Dixon  L;  Perkins  D;  Calmes  C: Guideline Watch (September 2009): Practice Guideline for the Treatment of Patients With Schizophrenia. Arlington, VA: American Psychiatric Association,  2009. Available from: http://www.psychiatryonline.com/pracGuide/PracticePDFs/Schizophrenia_Guideline%20Watch.pdf.

Dulcan  MK (ed):  Dulcan’s Textbook of Child and Adolescent Psychiatry .  Washington, DC,  American Psychiatric Publishing,  2010

 Duloxetine package insert. http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c3657589-4202-4d67-abb0-15df86eacd39#nlm

34067–9 Duvvuri V, Kaye WH: Anorexia nervosa clinical synthesis. Focus 2009; 7:459-460 Einarson A, Boskovic R: Use and safety of antipsychotic drugs during pregnancy. J Psychiatr Pract 2009; 15:183–192

Emslie  GJ;  Kennard  BD;  Mayes  TL;  Nightingale-Teresi  J;  Carmody  T;  Hughes  CW;  Rush  AJ;  Tao  R;  Rintelmann  JW:  Fluoxetine versus placebo in preventing relapse of major depression in children and adolescents.  Am J Psychiatry   2008; 165:459

467. Reprinted in FOCUS 2008; 6:355-356

Fabrazzo  M;  La Pia  S;  Monteleone  P;  Mennella  R;  Esposito  G;  Pinto  A;  Maj  M:  Fluvoxamine increases plasma and urinary levels of clozapine and its major metabolites in a time-and dose-dependent manner.  J Clin Psychopharmacol   2000; 20:708–710

 FDA:  Risk of oral birth defects in children born to mothers taking topiramate . http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm245594.htm.

Fitelson  E;  Kim  S;  Baker  AS;  Leight  K:  Treatment of postpartum depression: clinical, psychological and pharmacological options.  Int J Womens Health   2010; 3:1–14

Freeman  EW;  Rickels  K;  Sondheimer  SJ;  Polansky  M;  Xiao  S:  Continuous or intermittent dosing with sertraline for patients with severe premenstrual syndrome or premenstrual dysphoric disorder.  Am J Psychiatry   2004; 161:343–351

Galanter  M;  Kleber  HD (eds):  The American Psychiatric Publishing Textbook of Substance Abuse Treatment , 4th ed.  Washington, DC,  American Psychiatric Publishing,  2008.

Gaynes  BN;  Warden  D;  Trivedi  MH;  Wisniewski  SR;  Fava  M;  Rush  AJ:  What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depression.  Psychiatr Serv   2009; 60:1439–1445

George  MS;  Post  RM:  Daily left prefrontal repetitive transcranial magnetic stimulation for acute treatment of medication-resistant depression.  Am J Psychiatry   2011; 168:356–364

 GlaxoSmithKline: Change in the Pregnancy subsection of the PRECAUTIONS section in the labels for PAXIL (paroxetine HCl) and PAXIL CR (paroxetine HCl) Controlled-Release Tablets, Sept  2005. Accessed on August 10, 2011 from: http://www.fda.gov/downloads/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/UCM164865.pdf

Goldstein  BI:  Recent progress in understanding pediatric bipolar disorder.  Arch Pediatr Adolesc Med   2012; 166:362–371

Greenfield  SF;  Back  SE;  Lawson  K;  Brady  KT:  Substance abuse in women.  Psychiatr Clin North Am   2010; 33:339–355

Haas  SJ;  Hill  R;  Krum  H;  Liew  D;  Tonkin  A;  Demos  L;  Stephan  K;  McNeil  J:  Clozapine-associated myocarditis: a review of 116 cases of suspected myocarditis associated with the use of clozapine in Australia during 1993-2003.  Drug Saf   2007; 30:47–57

Haddad  PM;  Anderson  IM:  Antipsychotic-related QTc prolongation, torsade de pointes and sudden death.  Drugs   2002; 62:1649–1671

Haddad  PM;  Sharma  SG:  Adverse effects of atypical antipsychotics: differential risk and clinical implications.  CNS Drugs   2007; 21:911–936

Hales  RE;  Yudofsky  SC;  Gabbard  GO (eds): The American Psychiatric Publishing Textbook of Psychiatry, 5^th ed. Washington, DC, American Psychiatric Publishing,  2008.

http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PsychopharmacologicDrugsAdvisoryCommittee/UCM173876.pdf.

Jaquenoud Sirot  E;  Knezevic  B;  Morena  GP;  Harenberg  S;  Oneda  B;  Crettol  S;  Ansermot  N;  Baumann  P;  Eap  CB:  ABCB1 and cytochrome P450 polymorphisms: clinical pharmacogenetics of clozapine.  J Clin Psychopharmacol   2009; 29:319–326

Jefferson  JW:  Lamotrigine in psychiatry: pharmacology and therapeutics.  CNS Spectr   2005; 10:224–232

Kane  JM:  New-onset schizophrenia: pharmacologic treatment.  Focus   2008; 6:167–171

Kar  N:  Cognitive behavioral therapy for the treatment of post-traumatic stress disorder: a review.  Neuropsychiatr Dis Treat   2011; 7:167–181

Kreyenbuhl  J;  Marcus  SC;  West  JC;  Wilk  J;  Olfson  M:  Adding or switching antipsychotic medications in treatment-refractory schizophrenia. Psychiatr Serv   2007; 58:983–990. Focus 2008; 6:212–220

Leibenluft  E;  Rich  BA:  Pediatric bipolar disorder.  Annu Rev Clin Psychol .  2008; 4:163–87. Focus 2008; 6:334

Lichtman  JH;  Bigger  JT;  Blumenthal  JA;  Frasure-Smith  N;  Kaufmann  PG;  Lesperance  F;  Mark  DB;  Sheps  DS;  Taylor  CB;  Froelicher  ES:  Depression and coronary heart disease: Recommendations for screening, referral, and treatment: A Science Advisory From the American Heart Association Prevention Committee of the Council on Cardiovascular Nursing, Council on Clinical Cardiology, Council on Epidemiology and Prevention, and Interdisciplinary Council on Quality of Care and Outcomes Research: Endorsed by the American Psychiatric Association. Circulation 2008; 118:1768–1775.  Focus   2009; 7:406–413

Louik  C;  Lin  AE;  Werler  MM;  Hernández-Díaz  S;  Mitchell  AA:  First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects.  N Engl J Med   2007; 356:2675–2683

Ma  J;  Alvir  J;  Lieberman  JA;  Safferman  AZ;  Schwimmer  JL;  Schaaf  JA:  Clozapine-induced agranulocytosis–incidence and risk factors in the United States.  N Engl J Med   1993; 329:162–167

Madaan  V:  Assessment of panic disorder across the life span.  Focus   2008; 6:439

Markowitz  JC:  The clinical conduct of interpersonal psychotherapy.  Focus   2006; 4:179–184

Martin  A;  Volkmar  FR (ed):  Lewis’s Child and Adolescent Psychiatry , 4th ed.  Philadelphia,  Lippincott, Williams & Wilkins,  2007

Masi  G;  Liboni  F;  Brovedani  P:  Pharmacotherapy of major depressive disorder in adolescents.  Expert Opin Pharmacother   2010

11. : 375–386 McGavin JK, Goa KL:  Aripiprazole. CNS Drugs 2002; 16:779–786, discussion 787–788 Menon SJ: Psychotropic medication during pregnancy and lactation.  Arch Gynecol Obstet   2008; 277:1–13

Morrell  MJ;  Hayes  FJ;  Sluss  PM;  Adams  JM;  Bhatt  M;  Ozkara  C;  Warnock  CR;  Isojärvi  J:  Hyperandrogenism, ovulatory dysfunction, and polycystic ovary syndrome with valproate versus lamotrigine.  Ann Neurol   2008; 64:200–211

Murray  RM;  Van Os  J:  Predictors of outcome in schizophrenia.  J Clin Psychopharmacol   1998; 18(Suppl 1):2S–4S

Nelson  JC;  Papakostas  GI:  Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials.  Am J Psychiatry   2009; 166:980–991

Nemeroff  CB:  Recent findings in the pathophysiology of depression.  Focus   2008; 6:3–14

Norman  RM;  Manchanda  R;  Malla  AK;  Harricharan  R;  Northcott  S:  The significance of family history in first-episode schizophrenia spectrum disorder.  J Nerv Ment Dis   2007; 195:846–852

Oldham  JM;  Skodol  AE;  Bender  DS (ed):  Essentials of Personality Disorders .  Washington, DC,  American Psychiatric Publishing,  2009

Package insert for olanzapine extended release injectable suspension. Eli Lilly and Company. Revision July 5,  2011. http://pi.lilly.com/us/zyprexa-pi.pdf

Payne  JL:  Antidepressant use in the postpartum period: practical considerations.  Am J Psychiatry   2007; 164:1329–1332

Pearlstein  T;  Steiner  M:  Premenstrual dysphoric disorder: burden of illness and treatment update. J Psychiatry Neurosci 2008; 33:291-301.  Focus   2012; 10:90–101

Pinkerton  JV;  Stovall  DW;  Kightlinger  RS:  Advances in the treatment of menopausal symptoms.  Womens Health (Lond Engl)   2009; 5:361–384, quiz 383–384

Pliszka  SR;  Crismon  ML;  Hughes  CW;  Corners  CK;  Emslie  GJ;  Jensen  PS;  McCracken  JT;  Swanson  JM;  Lopez  M:  Texas Consensus Conference Panel on Pharmacotherapy of Childhood Attention Deficit Hyperactivity Disorder: The Texas Children’s Medication Algorithm Project: Revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder.  J Am Acad Child Adolesc Psychiatry   2006; 45:642–657. Reprinted in FOCUS 2008; 6:401–426.

Pliszka  S  et al.:  Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/ hyperactivity disorder. J Amer Acad Child Adolesc Psychiatry 2007; 46:894–921.  Focus   2008; 6:401–426

 Practice Guideline for the Treatment of Patients With Bipolar Disorder:  2002, in  American Psychiatric Association Practice Guidelines for the Treatment of Psychiatric Disorders, Compendium 2004 , 2nd ed.  Washington, DC,  APA,  2004, pp 572–573. [Reprinted in FOCUS 2003; 1:64–110 ] [pp 91–92] [ Practice Guideline for the Treatment of Patients With Schizophrenia Second Edition:] Arlington VA: American Psychiatric Association, 2004. http://psychiatryonline.org/content.aspx?bookid=28&sectionid=1665359

 Practice parameter for the assessment and treatment of children and adolescents with posttraumatic stress disorder.  J Am Acad Child Adolesc Psychiatry   2010; 49:421–424

Raedler  TJ:  Cardiovascular aspects of antipsychotics.  Curr Opin Psychiatry   2010; 23:574–581

Rathod  S;  Kingdon  D;  Weiden  P;  Turkington  D:  Cognitive-behavioral therapy for medication-resistant schizophrenia: a review.  Journal of Psychiatric Practice   2008; 14:22–33. Focus 2010; 8:626–637

Rettew  DC;  Stanger  C;  McKee  L;  Doyle  A;  Hudziak  JJ:  Interactions between child and parent temperament and child behavior problems. Compr Psychiatry 2006; 47:412–420.  Focus   2010; 8:282

Robinson  GE:  Psychopharmacology in pregnancy and postpartum.  Focus   2012; 10:3–14

Ronaldson  KJ;  Fitzgerald  PB;  Taylor  AJ;  Topliss  DJ;  McNeil  JJ:  A new monitoring protocol for clozapine-induced myocarditis based on an analysis of 75 cases and 94 controls.  Aust N Z J Psychiatry   2011; 45:458–465

Rush  AJ;  Trivedi  MH;  Stewart  JW;  Nierenberg  AA;  Fava  M;  Kurian  BT;  Warden  D;  Morris  DW;  Luther  JF;  Husain  MM;  Cook  IA;  Shelton  RC;  Lesser  IM;  Kornstein  SG;  Wisniewski  SR:  Combining Medications to Enhance Depression Outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study.  Am J Psychiatry   2011; 168:689–701

Rush  AJ;  Warden  D;  Wisniewski  SR;  Fava  M;  Trivedi  MH;  Gaynes  BN;  Nierenberg  AA:  STAR*D: revising conventional wisdom.  CNS Drugs   2009; 23:627–647

Sabers  A;  Buchholt  JM;  Uldall  P;  Hansen  EL:  Lamotrigine plasma levels reduced by oral contraceptives.  Epilepsy Res   2001; 47:151–154

Sadock  BJ;  Sadock  VA (ed):  Kaplan and Sadock’s Synopsis of Psychiatry, 10th ed.  Philadelphia,  Lippincott Williams & Wilkins,  2007

Schatzberg  AF;  Cole  JO;  DeBattista  C:  Manual of Clinical Psychopharmacology , 7th ed.  Washington, DC,  American Psychiatric Publishing,  2010

Schatzberg  AF;  Nemeroff  CB (eds):  The American Psychiatric Publishing Textbook of Psychopharmacology, 4th ed.  Washington, DC,  American Psychiatric Publishing,  2009.

Schechter  DS;  Willheim  E:  Disturbances of attachment and parental psychopathology in early childhood.  Child Adolesc Psychiatr Clin N Am   2009; 18:665–686

Seeman  MV:  Gender differences in the prescribing of antipsychotic drugs.  Am J Psychiatry   2004; 161:1324–1333. Reprinted in Focus 2006; 4:115–124

 Selegiline transdermal system package insert. Available from http://packageinserts.bms.com/pi/pi_emsam.pdf. Accessed on December 26, 2011

Simon  GE;  Savarino  J:  Suicide attempts among patients starting depression treatment with medications or psychotherapy.  Am J Psychiatry   2007; 164:1029–1034. Reprinted in FOCUS 2008; 6:80–85

Sindrup  SH;  Brøsen  K:  The pharmacogenetics of codeine hypoalgesia.  Pharmacogenetics   1995; 5:335–346

Soares  CN;  Murray  BJ:  Sleep disorders in women: clinical evidence and treatment strategies.  Psychiatr Clin North Am   2006; 29:1095–1113[abstract xi]

Spina  E;  Santoro  V;  D’Arrigo  C:  Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update.  Clin Ther   2008; 30:1206–1227

Spina  E;  Trifirò  G;  Caraci  F:  Clinically significant drug interactions with newer antidepressants.  CNS Drugs   2012; 26:39–67

Spinelli  MG:  Postpartum psychosis: detection of risk and management.  Am J Psychiatry   2009; 166:405–408

Stroup  TS;  McEvoy  JP;  Ring  KD;  Hamer  RH;  LaVange  LM;  Swartz  MS;  Rosenheck  RA;  Perkins  DO;  Nussbaum  AM;  Lieberman  JA:  Schizophrenia Trials Network: A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP).  Am J Psychiatry   2011; 168:947–956

Sullivan  PF;  Neale  MC;  Kendler  KS:  Genetic epidemiology of major depression: review and meta-analysis.  Am J Psychiatry   2000; 157:1552–1562

Suri  R;  Altshuler  L:  Postpartum depression: Advances in recognition and treatment.  Focus   2012; 10:15–21

Thioridazine package insert http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b8d8c29a-414d-4622-bffd-b742725b20f0

Tsoi  DT;  Porwal  M;  Webster  AC:  Interventions for smoking cessation and reduction in individuals with schizophrenia.  Cochrane Database Syst Rev   2010; (6):CD007253

Turkington  D;  Dudley  R;  Warman  DM;  Beck  AT:  Cognitive-behavioral therapy for schizophrenia: a review. Journal of Psychiatry Practice 2004; 10:5–16.  Focus   2006; 4:223–233

 U.S. Food and Drug Administration: FDA Executive Summary Prepared for the January 27-28, 2011 Meeting of the Neurological Devices Panel Meeting to Discuss the Classification of Electroconvulsive Therapy Devices (ECT). Available at: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/MedicalDevices/MedicalDevicesAdvisoryCommittee/NeurologicalDevicesPanel/UCM240933.pdf

Udechuku  A;  Nguyen  T;  Hill  R;  Szego  K:  Antidepressants in pregnancy: a systematic review.  Aust N Z J Psychiatry   2010; 44:978–996

 US Food and Drug Administration: Department of Health and Human Services: FDA Drug Safety Communication: Antipsychotic drug labels updated on use during pregnancy and risk of abnormal muscle movements and withdrawal symptoms in newborns. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm243903.htm.

Valentino  RM;  Foldvary-Schaefer  N:  Modafinil in the treatment of excessive daytime sleepiness.  Cleve Clin J Med   2007; 74:561–566, 568–571

 Vilazodone (Viibryd)—a new antidepressant.  Med Lett Drugs Ther   2011; 53:53–54

Vitiello  B;  Elliott  GR;  Swanson  JM;  Arnold  LE;  Hechtman  L;  Abikoff  H;  Molina  BS;  Wells  K;  Wigal  T;  Jensen  PS;  Greenhill  LL;  Kaltman  JR;  Severe  JB;  Odbert  C;  Hur  K;  Gibbons  R:  Blood pressure and heart rate over 10 years in the multimodal treatment study of children with ADHD.  Am J Psychiatry   2012; 169:167–177

Westphal  A;  Volkmar  FR:  An update on autism.  Focus   2008; 6:284–292

Wisner  KL;  Sit  DKY;  Hanusa  BH;  Moses-Kolko  EL;  Bogen  DL;  Hunker  DF  et al.:  Major depression and antidepressant treatment: impact on pregnancy and neonatal outcomes. Am J Psychiatry 2009; 166:557–566.  Focus   2009; 7:374–384

Yonkers KA, Vigod S, Ross LE: Diagnosis, pathophysiology, and management of mood disorders in pregnant and postpartum women. Obstet Gynecol 2011; 117:961–977 Reprinted in FOCUS Winter 2012; 10; 51–66

Yonkers KA, et al: The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. Arlington, VA, American Psychiatric Association, 2009. Reprinted in Focus Winter 2012; 10:78–89

Ziprasidone Prescribing Information: Pfizer, Inc., Nov, 2009. http://labeling.pfizer.com/ShowLabeling.aspx?id=584